PRINCETON, N.J., Jan. 9 /PRNewswire-FirstCall/ -- Novo Nordisk, a healthcare company with an 84-year history of innovation and achievement in diabetes care, today announced the appointment of Alan C. Moses, M.D. as vice president, chief medical officer worldwide. Moses is currently the chief medical officer of Novo Nordisk Inc., the company's U.S. affiliate.
"Alan has the unique talent to integrate the science of discovery with new drug development -- a critical asset that will deepen Novo Nordisk's leadership position in changing diabetes," said Mads Krogsgaard Thomsen, executive vice president and chief science officer for Novo Nordisk A/S. "The broadening of Novo Nordisk's diabetes therapeutic portfolio with the development of liraglutide and other novel molecules in the pipeline, and the increasing importance of the U. S. to the Novo Nordisk business, requires a leader with clinical and research expertise to assume the role of chief medical officer."
In the newly expanded role, Moses will work closely with senior colleagues in Denmark to serve as the principle voice of clinical science for the company worldwide, providing clinical and medical affairs expertise.
"Novo Nordisk and the diabetes community in the U.S. have been fortunate to have Alan lead the efforts for the company in changing diabetes, and now, with his expanded responsibilities, the world will benefit from Alan's passion for research and advocacy for finding better ways for people to live with the disease," said Dr. Henrik Rasmussen, vice president of clinical development, medical and regulatory affairs, Novo Nordisk Inc.
Moses was formerly senior vice president and chief medical officer at
the Joslin Diabetes Center and joined Novo Nordisk in April 2004 as
associate vice president of medical affairs and since then has also assumed
responsibility for clinical research in diabetes. Prior to joining Novo
Nordisk, Dr. Moses spent 23 years at Harvard Medical School-a
|SOURCE Novo Nordisk|
Copyright©2008 PR Newswire.
All rights reserved